Figures
In the Results subsection of the Abstract. there are numbers reported which are inconsistent with those of the main text. Please see the complete, correct Results subsection of the Abstract here:
Of 29,540 patients with MDD, 3,224 (10.9%) met the study definition of TRD; 157,590 were included in the non-MDD cohort. Matched patients with TRD and non-TRD MDD were, on average, 58.9 and 59.0 years old, respectively. The TRD cohort had higher per-patient-per-year (PPPY) HRU than the non-TRD MDD (e.g., inpatient visits: incidence rate ratio [IRR] = 1.34) and non-MDD cohorts (e.g., inpatient visits: IRR = 1.89, all P<0.001). The TRD cohort had significantly higher total PPPY healthcare costs than the non-TRD MDD cohort ($25,059 vs. $19,945, adjusted cost difference = $3,377) and non-MDD cohort ($25,059 vs. $14,410, adjusted cost difference = $3,675, all P<0.001). Similar results were found for the subset of patients ≥65.
There is an error in Table 1. The values in line 9 “Other/Unknown” are missing. Please see the complete, correct Table 1 here.
In the Baseline demographic and clinical characteristics subsection of the Results section, there are errors in the sixth sentence of the first paragraph. The correct sentence is:
The mean duration of the observation period was 21.6, 20.7, and 19.1 months in the TRD, non-TRD MDD, and the non-MDD cohort, respectively.
In the Costs subsection of the Results section, there is an error in the first sentence of the second paragraph. The correct sentence is:
All-cause PPPY medical costs drove the majority of the cost difference whether TRD patients were compared to those with non-TRD MDD or non-MDD (% of total adjusted cost difference: vs. TRD = 75.7%, vs. non-TRD MDD = 73.5%); outpatient costs were the main driver for both comparisons (Table 2).
In the Discussion section, there is an error in the second sentence of the fourth paragraph. The correct sentence is:
However, the difference appeared smaller than that observed in different populations (Medicare = $3,377, commercial = $6,709, Medicaid = $4,382) [12, 18], suggesting the incremental cost burden of TRD may be lower in Medicare-insured patients.
Reference
- 1. Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, et al. (2019) Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS ONE 14(10): e0223255. https://doi.org/10.1371/journal.pone.0223255 pmid:31600244
Citation: Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, et al. (2021) Correction: Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. PLoS ONE 16(4): e0249731. https://doi.org/10.1371/journal.pone.0249731
Published: April 1, 2021
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.